Welcome to our dedicated page for Petvivo Hldgs news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on Petvivo Hldgs stock.
PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) generates news across animal health, regenerative medicine and veterinary-focused artificial intelligence. The company, together with its subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., reports on developments in its veterinary medical devices, platelet-rich plasma products and AI platforms designed for companion animals and horses.
News coverage for PetVivo often highlights updates on its lead products SPRYNG® with OsteoCushion® technology and PrecisePRP®, including distribution agreements, clinical adoption by veterinary practices and educational initiatives such as continuing education courses and conference presentations. Press releases also describe how these products are promoted through vendor partnerships and distributor networks, as well as their use in managing osteoarthritis, lameness and other joint-related conditions in cats, dogs and horses.
Another key theme in PetVivo news is its expansion into veterinary AI and digital platforms. Announcements have detailed the launch of the PetVivo.ai platform, an AI-powered system intended to improve veterinary client acquisition and engagement through multiple specialized AI agents. Additional releases cover PetVivo’s exclusive 10-year white-label licensing agreement for the Agentic Pet AI framework, publication of a technical whitepaper validating this multi-agent architecture and plans for dual-platform launches that connect pet parents with veterinary practices.
Investors and veterinary professionals following PETV news can also see updates on strategic alliances, board appointments, investor conference presentations and financial results. Earnings-related releases describe revenue trends, product mix developments and distribution expansion, while corporate announcements provide insight into capital structure actions and governance changes. For ongoing context around PetVivo’s products, partnerships and AI initiatives, this news feed offers a centralized view of the company’s public disclosures.
PetVivo Holdings reported fiscal 2024 results, showing a 6% revenue increase to $969,000 and a gross profit of $740,000, or 76.3% of revenues. Sales of Spryng™, their lead veterinary medical device, rose by 15% to $732,000. Operating expenses increased 20% to $11.4 million, primarily due to higher general and administrative expenses and R&D costs. The net loss totaled $11.0 million or $(0.78) per share, compared to a net loss of $8.7 million or $(0.85) per share in fiscal 2023. The company plans further expansion in fiscal 2025, expecting net revenue of $1.5 million to $2.0 million.
Operationally, PetVivo achieved distribution of Spryng™ to over 700 veterinary clinics across 50 states and reported positive clinical study results. The company expanded its distribution network, partnering with Covetrus North America. New key appointments include Garry Lowenthal as CFO and Spencer Breithaupt to the board of directors.
PetVivo will hold a conference call on June 28, 2024, at 5:00 p.m. ET to discuss fiscal Q4 and annual results ended March 31, 2024. The financial results will be released prior to the call. Management will present and answer questions. Dial-in and webcast replay options are available.
PetVivo Holdings has appointed Bryan Monninger as their new VP of Sales. Monninger brings over 20 years of experience in sales and marketing, including senior roles at NOVUS, Colgate-Palmolive, Lintbells, and ConAgra. He will lead PetVivo's sales and distribution teams to expand the market adoption of their animal osteoarthritis product, Spryng™ with OsteoCushion™ Technology. Monninger's extensive background includes successful market entries, strategic planning, and sales growth acceleration. CEO John Lai expects Monninger's expertise to drive PetVivo's growth and expand their market reach both domestically and internationally.
PetVivo Holdings announced that April Boyce has joined as Vice President of Marketing. Boyce, with over 20 years of experience in consumer-packaged goods (CPG) marketing, sales, and strategic partnerships, has held significant roles at Procter & Gamble and Clorox. At Clorox, she led the shopper marketing division and formed strategic partnerships with companies like Burt's Bees, Coca-Cola, and Tyson Foods. Her most recent role was Chief Commercial Officer at pet tech start-up, Link. Boyce aims to enhance awareness and understanding of PetVivo's veterinary medical device, Spryng with OsteoCushion Technology.
FAQ
What is the current stock price of Petvivo Hldgs (PETV)?
What is the market cap of Petvivo Hldgs (PETV)?
